Literature DB >> 987848

Inhibitory and cytotoxic effects of Oncovin (Vincristine sulfate) on cells of human line NHIK 3025.

W N Dahl, R Oftebro, E O Pettersen, T Brustad.   

Abstract

The inhibitory effect of Oncovin (vincristine sulfate) on cell division was studied in human cell line NHIK 3025. Oncovin arrested the cells in metaphase at concentrations as low as 10(-3) mug/ml. At 8 X 10(-3) mug/ml and higher concentrations, the arrest was complete after 6 hr of treatment. The arrest was irreversible after exposure for 6 hr to 16 X 10(-3) mug Oncovin per ml. The X-ray radiosensitivity of aerobic cells of the same line pretreated with 16 X 10(-3) mug Oncovin per ml for 6 hr (Oncovin removed before irradiation) was found to be about equal to that of untreated cells. Even when present during irradiation, Oncovin did not exert any modifying effect on the radiosensitivity of either aerobic or extremely hypoxic cells.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 987848

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Mitotic arrest and interphase inhibition induced by the pyrimidine sulfoxide NY 4138.

Authors:  E O Pettersen; O Nome; J M Dornish; R Oftebro
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

2.  Structure-activity relationship of 1-propargyl-5-halopyrimidin-2-ones. Metaphase arresting properties and competitive inhibition of colchicine binding to tubulin.

Authors:  J M Dornish; R Oftebro
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Effects of the new mitotic inhibitor pyrimidinsulfone NY 4137 on human cells in vitro and on colchicine binding to tubulin.

Authors:  M E Nygaard; J M Dornish; R Oftebro; K Undheim
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  Pharmacokinetics of vincristine sulfate in children.

Authors:  V S Sethi; J C Kimball
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model.

Authors:  Georgios S Stamatakos; Eleni C Georgiadi; Norbert Graf; Eleni A Kolokotroni; Dimitra D Dionysiou
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

Review 6.  The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.

Authors:  Niklas Benedikt Pepper; Walter Stummer; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2022-05-03       Impact factor: 4.033

7.  Inactivation by the mitotic inhibitor NY 3170 of human cells in vitro.

Authors:  E Wibe; R Oftebro
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.